Drug Enforcement Administration

As the cannabis industry continues to blossom, it becomes increasingly important to spotlight those at the forefront of the green revolution. In this evolving landscape, visionaries are emerging, shaping the industry, societal perceptions and legal frameworks. Here are the stories and...

CURE Pharmaceutical Holding Corp (OTC: CURR) said Tuesday it managed to broaden its license from the U.S. Drug Enforcement Administration. The expanded license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD) will allow...

By William Sumner, Hemp Business Journal Contributor Last week, the hemp industry was abuzz with the news that the United States Drug Enforcement Administration (DEA) would move Epidiolex, a CBD-based drug derived from cannabis, from a Schedule I substance to a Schedule V substance. The scheduling...

Drug distributors were in freefall Friday when CBS Corporation (NYSE: CBS) teased an expository “60 Minutes” episode linking these distributors to failures in the opioid crackdown. The Oct. 15 segment will highlight a joint investigation with The Washington Post revealing hindrances to...

On Tuesday, Attorney General Eric Holder announced that the head of the Drug Enforcement Administration Michele Leonhart was stepping down in May. The announcement follows weeks of criticism over her handling of reports that FBI agents were attending sex parties paid for by drug cartels in Colombia...